SCHEMBL7967307

SCHEMBL7967307

CO[CH]c1cc(C)c2ccccc2n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.61
L3MBTL1 Q9Y468 4/20 0.61
MAPT P10636 4/20 0.61
POLB P06746 3/20 0.61
RAB9A P51151 2/20 0.61
CYP1A2 P05177 1/20 0.55
BACE1 P56817 1/20 0.51
LMNA P02545 2/20 0.49
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 3/20 0.44
GAA P10253 2/20 0.44
NPFFR1 Q9GZQ6 1/20 0.44
NPFFR2 Q9Y5X5 1/20 0.44
HPGD P15428 1/20 0.43
LRRK2 Q5S007 1/20 0.43
ACHE P22303 1/20 0.43
TP53 P04637 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3085387 0.80 KDM4E (0.67) KDM4EL3MBTL1MAPTPOLBRAB9A
SCHEMBL6456809 0.79 KDM4E (0.65) KDM4EL3MBTL1MAPTPOLBRAB9A
SCHEMBL3086829 0.79 KDM4E (0.65) KDM4EL3MBTL1MAPTPOLBRAB9A
SCHEMBL12408803 0.77 KDM4E (0.73) KDM4EL3MBTL1MAPTPOLBRAB9A
SCHEMBL14279421 0.76 KDM4E (1.00) KDM4EL3MBTL1MAPTPOLBRAB9A
SCHEMBL4810314 0.76 KDM4E (1.00) KDM4EL3MBTL1MAPTPOLBRAB9A
SCHEMBL423891 0.73 L3MBTL1 (0.71) KDM4EL3MBTL1MAPTPOLBRAB9A
SCHEMBL1088580 0.71 CYP1A2 (0.69) KDM4EL3MBTL1MAPTPOLBRAB9A
SCHEMBL29502790 0.71 CYP1A2 (1.00) KDM4EL3MBTL1MAPTPOLBRAB9A
SCHEMBL89010 0.71 CYP1A2 (1.00) KDM4EL3MBTL1MAPTPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6274715-B1 SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY ABBOTT LABORATORIES 2001-08-14 US claimed
CN-1244202-A Tricyclic erythromycin derivatives ABBOTT LAB (US) 2000-02-09 CN claimed
EP-0961776-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES Abbott Laboratories (US) 1999-12-08 EP claimed
WO-1998030574-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1998-07-16 WO claimed
US-6274715-B1 SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY ABBOTT LABORATORIES 2001-08-14 US disclosed
CN-1244202-A Tricyclic erythromycin derivatives ABBOTT LAB (US) 2000-02-09 CN disclosed
EP-0961776-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES Abbott Laboratories (US) 1999-12-08 EP disclosed
WO-1998030574-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1998-07-16 WO disclosed